Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 80 mg; amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; crospovidone; hypromellose; purified talc; iron oxide yellow; macrogol 4000; titanium dioxide - treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Israel - English - Ministry of Health

novartis israel ltd - amlodipine as besylate; valsartan - film coated tablets - amlodipine as besylate 5 mg; valsartan 80 mg - amlodipine - amlodipine - treatment of essential hypertension. exforge is indicated for patients whose blood pressure is not adequately controlled on monotherapy.

Israel - English - Ministry of Health

novartis israel ltd - amlodipine as besylate; valsartan - film coated tablets - amlodipine as besylate 5 mg; valsartan 160 mg - amlodipine - amlodipine - treatment of essential hypertension. exforge is indicated for patients whose blood pressure is not adequately controlled on monotherapy.

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

novartis pharma stein ag - amlodipine (amlodipine besilate), valsartan, hydrochlorothiazide - tablets film-coated - 10mg+ 160mg+ 12,5mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

novartis pharma stein ag - amlodipine (amlodipine besilate), valsartan, hydrochlorothiazide - tablets film-coated - 10mg+ 160mg+ 25mg

Israel - English - Ministry of Health

novartis israel ltd - amlodipine as besylate; valsartan - film coated tablets - amlodipine as besylate 10 mg; valsartan 160 mg - amlodipine - amlodipine - treatment of essential hypertension. exforge is indicated for patients whose blood pressure is not adequately controlled on monotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 25 mg; valsartan, quantity: 320 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; crospovidone; hypromellose; purified talc; iron oxide yellow; macrogol 4000 - exforge hct is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 25 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); valsartan, quantity: 160 mg - tablet, film coated - excipient ingredients: crospovidone; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; hypromellose; purified talc; iron oxide yellow; macrogol 4000 - exforge hct is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); valsartan, quantity: 160 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; hypromellose; purified talc; iron oxide red; macrogol 4000; titanium dioxide; iron oxide yellow - exforge hct is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg); valsartan, quantity: 160 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; crospovidone; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; macrogol 4000; iron oxide yellow - exforge hct is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).